Organon & Co.は期待を裏切ったが,株価は"Hold"の評価で高騰した. Organon & Co. missed earnings expectations, yet its stock opened higher amid a "Hold" rating.

製薬会社 オルガンン・アンド・コーは,四半期毎の利益を1株当たり0.83ドルと報告し,分析家の予想である0.92ドルを落とした. Organon & Co., a pharmaceutical company, reported quarterly earnings of $0.83 per share, falling short of analysts' expectations of $0.92. 女性の健康と生態の相互関係に焦点をあてた同社は,約40億ドルの市場キャップを備え,アナリストから2.33ドルの目標価格を掲げた"安定"評価を実施している. The company, which focuses on women's health and biosimilars, has a market cap of about $4 billion and a "Hold" rating from analysts with a target price of $21.33. 利益目標が達成できず,株価は前回の閉店値より高くなって,正のギャップを示した. Despite missing earnings targets, the stock showed a positive gap up, opening higher than its previous close.